Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On May 14, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., had shares of common stock withheld by the issuer to satisfy tax withholding requirements.
- A total of 184 shares were withheld at a price of $8.36 per share.
- Following the transaction, Miller beneficially owns 39,709 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reports a routine transaction (tax withholding) and has a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a standard tax withholding procedure.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of stock transaction (tax withholding) |
| 05/16/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.